Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer

Kaibori, Masaki; Iwamoto, Yoshinori; Ishizaki, Morihiko; Matsui, Kosuke; Yoshioka, Kazuhiko; Asano, Hiroaki; Kwon, A‐Hon

doi:10.1007/s00423-011-0861-0

Cited by 31 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients treated for colorectal cancer or hepatic metastases, postoperative complications have been shown to correlate with recurrent disease. 8,30 More recently, the same association has been made in CRS þ IPC for colorectal cancer. 16,31 Accordingly, fewer postoperative complications were observed in patients with long-term disease free survival.…”

Section: Discussionmentioning

confidence: 72%

“…Other factors such as a favorable tumor histology and low nodal status are also important. 5e7 Comparable to the surgical treatment of liver metastases, 8 disease recurrence is a strong negative prognostic factor for survival. 9 In PC, even though a macroscopic complete resection is achieved in the majority of patients treated with CRS and IPC, recurrent disease is very common.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review

Oudheusden

Nienhuijs

Luyer

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review

Oudheusden

Nienhuijs

Luyer

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

“…All identified studies were observational design studies involving a total of 10621 patients. Seven studies were from USA [5, 7, 9, 16, 21, 22, 24], four from Italy [4, 8, 12, 13], three from Japan [3, 14, 18], two from UK [11, 25], two from Germany [20, 23], one from Sweden [2], one from France [6], one from Spain [10], one from Brazil [15], one from China [17], one from Canada [19], and one from the Netherlands [26]. The blood product transfusion rate was highly variable across studies ranging from 13.5% to 91.5%.…”

Section: Resultsmentioning

confidence: 99%

“…The impact of PBT on perioperative outcomes was evaluated in 6 studies [5, 11, 13, 14, 16, 20]. As shown in Figure 2, compared with nontransfused patients, transfused patients experienced higher overall morbidity ( P <0.001), more major complication (Clavien-Dindo class 3–5 [27]) ( P =0.005), higher mortality ( P <0.001), and longer lengths of hospital stay ( P <0.001).…”

Section: Resultsmentioning

confidence: 99%

Impact of perioperative blood transfusion on clinical outcomes in patients with colorectal liver metastasis after hepatectomy: a meta-analysis

Lyu

Qiao

et al. 2017

Oncotarget

View full text Add to dashboard Cite

BACKGROUNDPerioperative blood transfusion may be associated with negative clinical outcomes in oncological surgery. A meta-analysis of published studies was conducted to evaluate the impact of blood transfusion on short- and long-term outcomes following liver resection of colorectal liver metastasis (CLM).MATERIALS AND METHODSA systematic search was performed to identify relevant articles. Data were pooled for meta-analysis using Review Manager version 5.3.RESULTSTwenty-five observational studies containing 10621 patients were subjected to the analysis. Compared with non-transfused patients, transfused patients experienced higher overall morbidity (odds ratio [OR], 1.98; 95% confidence intervals [CI] =1.49-2.33), more major complications (OR, 2.12; 95% CI =1.26-3.58), higher mortality (OR, 4.13; 95% CI =1.96-8.72), and longer length of hospital stay (weighted mean difference, 4.43; 95% CI =1.15-7.69). Transfusion was associated with reduced overall survival (risk ratio [RR], 1.24, 95% CI =1.11-1.38) and disease-free survival (RR, 1.38, 95% CI=1.23-1.56).CONCLUSIONPerioperative blood transfusion has a detrimental impact on the clinical outcomes of patients undergoing CLM resection.

show abstract

“…CRLM. [14][15][16][24][25][26][27] The optimal time point to differentiate between early and late recurrence after curative hepatic resection for NELM remains, however, undefined. In the current study, 3 years was proposed as the appropriate cutoff to categorize patients as early versus late recurrence.…”

Section: Discussionmentioning

confidence: 99%

Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment

Zhang

Beal

Chakedis

et al. 2017

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Background Early tumor recurrence after curative resection typically indicates a poor prognosis. The objective of the current study was to investigate the risk factors, treatment, and prognosis of early recurrence of neuroendocrine tumor (NET) liver metastasis (NELM) after hepatic resection. Methods A total of 481 patients who underwent curative-intent resection for NELM were identified from a multiinstitutional database. Data on clinicopathological characteristics, intraoperative details, and outcomes were documented. The optimal cutoff value to differentiate early and late recurrence was determined to be 3 years based on linear regression. Results With a median follow-up of 60 months, 223 (46.4%) patients developed a recurrence, including 158 (70.9%) early and 65 (29.1%) late recurrences. On multivariable analysis, pancreatic NET, primary tumor lymph node metastasis, and a microscopic positive surgical margin were independent risk factors for early intrahepatic recurrence. While recurrence patterns and treatments were comparable among patients with early and late recurrences, early recurrence was associated with worse diseasespecific survival than late recurrences (10-year NELM-specific survival, 44.5 vs 75.8%, p < 0.001). Among the 34 (21.5%) patients who underwent curative treatment for early recurrence, post-recurrence disease-specific survival was better than noncuratively treated patients (10-year NELM-specific survival, 54.2 vs 26.3%, p = 0.028), yet similar to patients with late recurrences treated with curative intent (10-year NELM-specific survival, 54.2 vs 37.4%, p = 0.519). Conclusions Early recurrence after surgery for NELM was associated with the pancreatic type, primary lymph node metastasis, and extrahepatic disease. Re-treatment with curative intent prolonged survival after recurrence, and therefore, operative intervention even for early recurrences of NELM should be considered.

show abstract

Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer

Cited by 31 publications

References 40 publications

Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review

Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review

Impact of perioperative blood transfusion on clinical outcomes in patients with colorectal liver metastasis after hepatectomy: a meta-analysis

Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment

Contact Info

Product

Resources

About